This is due to: ‘R&D in the pharmaceutical industry 2022’ report, Farmaindustria, led by Jesús Ponce, president of the employers’ association and the pharmaceutical company Novartis. The resulting investment is 10.1% more than 2021 and the largest increase in the last 15 years, and continues to consolidate the pharmaceutical industry in both relative and absolute terms as the first industrial sector in R&D investment in our country.
60% of the investment was allocated to the development of clinical trials5.6% more than the previous year. In our country, companies’ commitment to conduct clinical research has increased every year, from 479 million euros recorded in 2012 to 834 million euros in 2022, which means a growth of over 74%. For many pharmaceutical companies, Spain ranks second in the world behind the United States in clinical trials, participating in one in three trials initiated in Europe.
Within the scope of this investment early stage trials (I and II) It increased by almost 10 points over the last 10 years, representing 36.4% of the total allocated in 2022. Phase III clinical trials with larger numbers of patients maintain their weight and percentage of investment for Phase IV. After the commercialization of the drug, its financial allocation remained stable during these years.
The second highest item is the most complex, allocated to research in the basic and pre-clinical stages, and represents an investment of 175 million euros, an increase of more than 11% compared to 2021. This is followed by €114 million allocated to technological development, with a further $105 million allocated to pharmacoeconomics, epidemiology and post-registration studies.
“Patients benefit above all from this investment, because a large part of it is devoted to the launch of clinical trials, which means that thousands of people in Spain have early access to the treatments of the future, that new medicine, that new innovative treatment.” For his illness, which will come to light in four or five years if all goes well. And for many patients with serious diseases, this represents a unique opportunity to cure their illness,” says Juan Yermo, managing director of Farmaindustria.
In the survey, almost half of the participants investment in spain633 million euros were allocated to “extra-urban research”, that is, research contracts in cooperation with hospitals, universities, public and private centres. An important contribution that continues to highlight the important role that public-private partnerships play in the sustainability of these centers and facilitates patients’ access to cutting-edge treatments through clinical trials. According to the National Institute of Statistics (INE), the pharmaceutical industry is the leading sector of the Spanish economy in terms of extramural or collaborative investments, accounting for around a third of the national total. Industrial sector.
Finally, among the data provided by the ‘R&D in the pharmaceutical industry 2022’ research, continuous growth work straight It currently stands at 5,498 people, the highest number recorded in companies in investigation departments. Moreover, this employment is equitable – 67% of professionals working in R&D departments are women – and highly qualified: in 2022, 90% of university graduates in this field will be surpassed for the first time.